The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06890598




Registration number
Help: Registration number
NCT06890598
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
18/03/2025
Date registered
Help: Date registered
24/03/2025
Date last updated
Help: Date last updated
4/11/2026

Titles & IDs
Public title
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Scientific title
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
Additional trial identifiers [1] 0 0
2024-512302-25-00
Additional trial identifiers [2] 0 0
18763
Universal Trial Number (UTN)
Trial acronym
SUNRAY-02
Related trial records

Health condition
Health condition(s) studied:
Carcinoma, Non-Small-Cell Lung 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Non small cell

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - Olomorasib
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Durvalumab
Treatment: Drugs - Placebo

Experimental: Part A: Olomorasib + Pembrolizumab - Participants will receive olomorasib administered orally in combination with pembrolizumab intravenously (IV) for up to 1 year followed by olomorasib alone for up to 3 years of total treatment.

Placebo comparator: Part A: Placebo + Pembrolizumab - Participants will receive placebo administered orally in combination with pembrolizumab administered IV for up to 1 year followed by placebo alone for up to 3 years of total treatment.

Experimental: Part B: Olomorasib + Durvalumab - Participants will receive olomorasib administered orally in combination with durvalumab administered IV for up to 1 year followed by olomorasib alone for up to 3 years of total treatment.

Placebo comparator: Part B: Placebo + Durvalumab - Participants will receive placebo administered orally in combination with durvalumab administered IV for up to 1 year followed by placebo alone for up to 3 years of total treatment.


Treatment: Drugs: Olomorasib
Administered orally.

Treatment: Drugs: Pembrolizumab
Administered intravenously (IV).

Treatment: Drugs: Durvalumab
Administered IV.

Treatment: Drugs: Placebo
Administered orally.

Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Part A: Disease-Free Survival (DFS) by Investigator Assessment
Timepoint [1] 0 0
Randomization to disease recurrence or death from any cause (Estimated as approximately 4 years).
Primary outcome [2] 0 0
Part B: Progression-Free Survival (PFS) by BICR
Timepoint [2] 0 0
Randomization to disease progression or death from any cause (Estimated as approximately 3 years).
Secondary outcome [1] 0 0
Part A & B: Overall Survival (OS)
Timepoint [1] 0 0
Randomization to disease progression or death from any cause (Estimated as approximately 5 years).
Secondary outcome [2] 0 0
Part A & B: Change from baseline in health-related quality of life (HRQoL), measured by European Organization for Research & Treatment of CancerQualityofLifeQuestionnaire-Core 30 (EORTC QLQ-C30)
Timepoint [2] 0 0
Randomization through end of treatment (Estimated as approximately 3 years).
Secondary outcome [3] 0 0
Part B: PFS by Investigator
Timepoint [3] 0 0
Randomization to disease progression or death from any cause (Estimated as approximately 3 years)
Secondary outcome [4] 0 0
Part B: Objective Response Rate (ORR) per RECIST 1.1 by BICR and Investigator
Timepoint [4] 0 0
Randomization to disease progression or death from any cause (Estimated as approximately 3 years).
Secondary outcome [5] 0 0
Part B: Duration of Response (DOR) per RECIST 1.1 by BICR and Investigator
Timepoint [5] 0 0
Randomization to disease progression or death from any cause (Estimated as approximately 3 years).
Secondary outcome [6] 0 0
Part B: Disease Control Rate (DCR) per RECIST 1.1 by BICR and Investigator
Timepoint [6] 0 0
Randomization to disease progression or death from any cause (Estimated as approximately 3 years).
Secondary outcome [7] 0 0
Part B: Time to Response (TTR) per RECIST 1.1 by BICR and Investigator
Timepoint [7] 0 0
Randomization until the date that measurement criteria for CR or PR (whichever is first recorded) are first met (Estimated as approximately 3 years).
Secondary outcome [8] 0 0
Part B: Progression-Free Survival 2 (PFS2) by investigator assessment
Timepoint [8] 0 0
Randomization to disease progression on next line of treatment or death from any cause (Estimated as approximately 3 years).]
Secondary outcome [9] 0 0
Part B: Changes in Non-Small Cell Lung Cancer (NSCLC)-related symptoms, measured by the NSCLC-Symptom Assessment Questionnaire (SAQ)
Timepoint [9] 0 0
Randomization through end of treatment (Estimated as approximately 3 years).
Secondary outcome [10] 0 0
Part B: Time to worsening of NSCLC-related symptoms, as measured by NSCLC-SAQ
Timepoint [10] 0 0
Randomization through end of treatment (Estimated as approximately 3 years).
Secondary outcome [11] 0 0
Part B: Changes in patient-reported pulmonary symptoms of cough, chest pain, and dyspnea, measured by NSCLC-SAQ
Timepoint [11] 0 0
Randomization through end of treatment (Estimated as approximately 3 years).

Eligibility
Key inclusion criteria
* Histological or cytological confirmation of NSCLC.

* Part A

1. Clinical Stage II-IIIB (N0, N1, N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible.
2. Pathologic Stage II-IIIB (N0, N1, N2) NSCLC treated with initial upfront resection.
* Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.
* Must have disease with evidence of KRAS G12C mutation.
* Must have known programmed death-ligand 1 (PD-L1) expression
* Must have an ECOG performance status of 0 or 1.
* Able to swallow oral medication.
* Must have adequate laboratory parameters.
* Contraceptive use should be consistent with local regulations for those participating in clinical studies.
* Women of childbearing potential must

* Have a negative pregnancy test.
* Not be breastfeeding during treatment
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
* Have known, actionable changes in the EGFR or ALK genes.
* Have another type of cancer that is progressing or required active treatment within the past 2 years before screening.
* Have an active autoimmune disease that required systemic treatment in the past 2 years. Endocrine replacement therapy is allowed.
* Had any immune-related side effect or allergic reaction (Grade 3 or higher) from a previous immunotherapy medicine, or any immune-related side effect greater than Grade 1 that has not resolved. This does not apply for people with hormone-related diseases who are now on stable hormone replacement therapy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Icon Cancer Centre Wesley - Auchenflower
Recruitment hospital [2] 0 0
Sunshine Coast University Hospital - Birtinya
Recruitment hospital [3] 0 0
Austin Health - Heidelberg
Recruitment hospital [4] 0 0
ICON Cancer Centre - Kurralta Park - Kurralta Park
Recruitment hospital [5] 0 0
Tamworth Hospital - North Tamworth
Recruitment hospital [6] 0 0
Sir Charles Gairdner Hospital - Perth
Recruitment hospital [7] 0 0
Goulburn Valley Health - Shepparton
Recruitment hospital [8] 0 0
Latrobe Regional Health - Traralgon
Recruitment postcode(s) [1] 0 0
4066 - Auchenflower
Recruitment postcode(s) [2] 0 0
4575 - Birtinya
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [5] 0 0
2340 - North Tamworth
Recruitment postcode(s) [6] 0 0
6009 - Perth
Recruitment postcode(s) [7] 0 0
3630 - Shepparton
Recruitment postcode(s) [8] 0 0
3844 - Traralgon
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maine
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Missouri
Country [18] 0 0
United States of America
State/province [18] 0 0
New Hampshire
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oregon
Country [24] 0 0
United States of America
State/province [24] 0 0
Pennsylvania
Country [25] 0 0
United States of America
State/province [25] 0 0
South Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
South Dakota
Country [27] 0 0
United States of America
State/province [27] 0 0
Tennessee
Country [28] 0 0
United States of America
State/province [28] 0 0
Texas
Country [29] 0 0
United States of America
State/province [29] 0 0
Vermont
Country [30] 0 0
United States of America
State/province [30] 0 0
Virginia
Country [31] 0 0
United States of America
State/province [31] 0 0
Washington
Country [32] 0 0
United States of America
State/province [32] 0 0
Wisconsin
Country [33] 0 0
Austria
State/province [33] 0 0
Graz
Country [34] 0 0
Austria
State/province [34] 0 0
Linz
Country [35] 0 0
Austria
State/province [35] 0 0
Vienna
Country [36] 0 0
Belgium
State/province [36] 0 0
Auderghem
Country [37] 0 0
Belgium
State/province [37] 0 0
Edegem
Country [38] 0 0
Belgium
State/province [38] 0 0
Leuven
Country [39] 0 0
Belgium
State/province [39] 0 0
Roeselare
Country [40] 0 0
Brazil
State/province [40] 0 0
Barretos
Country [41] 0 0
Brazil
State/province [41] 0 0
Belém
Country [42] 0 0
Brazil
State/province [42] 0 0
Belo Horizonte
Country [43] 0 0
Brazil
State/province [43] 0 0
Bento Gonçalves
Country [44] 0 0
Brazil
State/province [44] 0 0
Campinas
Country [45] 0 0
Brazil
State/province [45] 0 0
Fortaleza
Country [46] 0 0
Brazil
State/province [46] 0 0
Londrina
Country [47] 0 0
Brazil
State/province [47] 0 0
Natal
Country [48] 0 0
Brazil
State/province [48] 0 0
Porto Alegre
Country [49] 0 0
Brazil
State/province [49] 0 0
Rio de Janeiro
Country [50] 0 0
Brazil
State/province [50] 0 0
São Paulo
Country [51] 0 0
Chile
State/province [51] 0 0
Providencia
Country [52] 0 0
Chile
State/province [52] 0 0
Santiago
Country [53] 0 0
China
State/province [53] 0 0
Anyang
Country [54] 0 0
China
State/province [54] 0 0
Beijing
Country [55] 0 0
China
State/province [55] 0 0
Changchun
Country [56] 0 0
China
State/province [56] 0 0
Changsha
Country [57] 0 0
China
State/province [57] 0 0
Chengdu
Country [58] 0 0
China
State/province [58] 0 0
Chongqing
Country [59] 0 0
China
State/province [59] 0 0
Foshan
Country [60] 0 0
China
State/province [60] 0 0
Guangzhou
Country [61] 0 0
China
State/province [61] 0 0
Hangzhou
Country [62] 0 0
China
State/province [62] 0 0
Harbin
Country [63] 0 0
China
State/province [63] 0 0
Jinan
Country [64] 0 0
China
State/province [64] 0 0
Linhai
Country [65] 0 0
China
State/province [65] 0 0
Liuzhou
Country [66] 0 0
China
State/province [66] 0 0
Luoyang
Country [67] 0 0
China
State/province [67] 0 0
Nanning
Country [68] 0 0
China
State/province [68] 0 0
Shanghai
Country [69] 0 0
China
State/province [69] 0 0
Shantou
Country [70] 0 0
China
State/province [70] 0 0
Shenzhen
Country [71] 0 0
China
State/province [71] 0 0
Suzhou
Country [72] 0 0
China
State/province [72] 0 0
Tianjin
Country [73] 0 0
China
State/province [73] 0 0
Wuhan
Country [74] 0 0
China
State/province [74] 0 0
Xi'an
Country [75] 0 0
China
State/province [75] 0 0
Zhongshan
Country [76] 0 0
Czechia
State/province [76] 0 0
Ostrava
Country [77] 0 0
Czechia
State/province [77] 0 0
Prague
Country [78] 0 0
France
State/province [78] 0 0
Bobigny
Country [79] 0 0
France
State/province [79] 0 0
Bron
Country [80] 0 0
France
State/province [80] 0 0
La Tronche
Country [81] 0 0
France
State/province [81] 0 0
Lyon Cedex08
Country [82] 0 0
France
State/province [82] 0 0
Marseille
Country [83] 0 0
France
State/province [83] 0 0
Nice
Country [84] 0 0
France
State/province [84] 0 0
Paris
Country [85] 0 0
France
State/province [85] 0 0
Pessac
Country [86] 0 0
France
State/province [86] 0 0
Poitiers
Country [87] 0 0
France
State/province [87] 0 0
Reims
Country [88] 0 0
France
State/province [88] 0 0
Rennes
Country [89] 0 0
France
State/province [89] 0 0
Toulouse
Country [90] 0 0
France
State/province [90] 0 0
Vantoux
Country [91] 0 0
France
State/province [91] 0 0
Villejuif
Country [92] 0 0
Germany
State/province [92] 0 0
Berlin
Country [93] 0 0
Germany
State/province [93] 0 0
Chemnitz
Country [94] 0 0
Germany
State/province [94] 0 0
Cologne
Country [95] 0 0
Germany
State/province [95] 0 0
Erfurt
Country [96] 0 0
Germany
State/province [96] 0 0
Gauting
Country [97] 0 0
Germany
State/province [97] 0 0
Georgsmarienhütte
Country [98] 0 0
Germany
State/province [98] 0 0
Großhansdorf
Country [99] 0 0
Germany
State/province [99] 0 0
Halle
Country [100] 0 0
Germany
State/province [100] 0 0
Hamburg
Country [101] 0 0
Germany
State/province [101] 0 0
Heidelberg
Country [102] 0 0
Germany
State/province [102] 0 0
Hemer
Country [103] 0 0
Germany
State/province [103] 0 0
Herne
Country [104] 0 0
Germany
State/province [104] 0 0
Leipzig
Country [105] 0 0
Germany
State/province [105] 0 0
Nuremberg
Country [106] 0 0
Germany
State/province [106] 0 0
Stuttgart
Country [107] 0 0
Germany
State/province [107] 0 0
Tübingen
Country [108] 0 0
Greece
State/province [108] 0 0
Athens
Country [109] 0 0
Greece
State/province [109] 0 0
Heraklion
Country [110] 0 0
Greece
State/province [110] 0 0
Larissa
Country [111] 0 0
Greece
State/province [111] 0 0
Pátrai
Country [112] 0 0
Greece
State/province [112] 0 0
Thessaloniki
Country [113] 0 0
Hungary
State/province [113] 0 0
Budapest
Country [114] 0 0
Hungary
State/province [114] 0 0
Farkasgyepu
Country [115] 0 0
India
State/province [115] 0 0
Ahmedabad
Country [116] 0 0
India
State/province [116] 0 0
Chennai
Country [117] 0 0
India
State/province [117] 0 0
Chhatrapati Sambhajinagar
Country [118] 0 0
India
State/province [118] 0 0
Mumbai
Country [119] 0 0
India
State/province [119] 0 0
Namakkal
Country [120] 0 0
India
State/province [120] 0 0
Patna
Country [121] 0 0
India
State/province [121] 0 0
Pune
Country [122] 0 0
India
State/province [122] 0 0
Thalassery
Country [123] 0 0
India
State/province [123] 0 0
Thiruvananthapuram
Country [124] 0 0
India
State/province [124] 0 0
Udaipur
Country [125] 0 0
India
State/province [125] 0 0
Varanasi
Country [126] 0 0
Israel
State/province [126] 0 0
Haifa
Country [127] 0 0
Israel
State/province [127] 0 0
Jerusalem
Country [128] 0 0
Israel
State/province [128] 0 0
Kfar Saba
Country [129] 0 0
Israel
State/province [129] 0 0
Ramat Gan
Country [130] 0 0
Italy
State/province [130] 0 0
Bari
Country [131] 0 0
Italy
State/province [131] 0 0
Catania
Country [132] 0 0
Italy
State/province [132] 0 0
Genova
Country [133] 0 0
Italy
State/province [133] 0 0
Meldola
Country [134] 0 0
Italy
State/province [134] 0 0
Milan
Country [135] 0 0
Italy
State/province [135] 0 0
Monza
Country [136] 0 0
Italy
State/province [136] 0 0
Naples
Country [137] 0 0
Italy
State/province [137] 0 0
Orbassano
Country [138] 0 0
Italy
State/province [138] 0 0
Rome
Country [139] 0 0
Italy
State/province [139] 0 0
Verona
Country [140] 0 0
Japan
State/province [140] 0 0
Bunkyo City
Country [141] 0 0
Japan
State/province [141] 0 0
Fukuoka
Country [142] 0 0
Japan
State/province [142] 0 0
Hidaka
Country [143] 0 0
Japan
State/province [143] 0 0
Himeji
Country [144] 0 0
Japan
State/province [144] 0 0
Hirakata
Country [145] 0 0
Japan
State/province [145] 0 0
Kanazawa
Country [146] 0 0
Japan
State/province [146] 0 0
Kashiwa
Country [147] 0 0
Japan
State/province [147] 0 0
Kobe
Country [148] 0 0
Japan
State/province [148] 0 0
Koto City
Country [149] 0 0
Japan
State/province [149] 0 0
Kyoto
Country [150] 0 0
Japan
State/province [150] 0 0
Nagaizumi-cho,Sunto-gun
Country [151] 0 0
Japan
State/province [151] 0 0
Nagoya
Country [152] 0 0
Japan
State/province [152] 0 0
Natori
Country [153] 0 0
Japan
State/province [153] 0 0
Niigata
Country [154] 0 0
Japan
State/province [154] 0 0
Sakai
Country [155] 0 0
Japan
State/province [155] 0 0
Sapporo
Country [156] 0 0
Japan
State/province [156] 0 0
Wakayama
Country [157] 0 0
Japan
State/province [157] 0 0
Yokohama
Country [158] 0 0
Japan
State/province [158] 0 0
Yonago
Country [159] 0 0
Netherlands
State/province [159] 0 0
Amsterdam
Country [160] 0 0
Netherlands
State/province [160] 0 0
Breda
Country [161] 0 0
Netherlands
State/province [161] 0 0
Harderwijk
Country [162] 0 0
Netherlands
State/province [162] 0 0
Maastricht
Country [163] 0 0
Netherlands
State/province [163] 0 0
Tilburg
Country [164] 0 0
Netherlands
State/province [164] 0 0
Utrecht
Country [165] 0 0
Netherlands
State/province [165] 0 0
Zwolle
Country [166] 0 0
Norway
State/province [166] 0 0
Arendal
Country [167] 0 0
Norway
State/province [167] 0 0
Bergen
Country [168] 0 0
Norway
State/province [168] 0 0
Drammen
Country [169] 0 0
Norway
State/province [169] 0 0
Gjøvik
Country [170] 0 0
Norway
State/province [170] 0 0
Oslo
Country [171] 0 0
Poland
State/province [171] 0 0
Kielce
Country [172] 0 0
Poland
State/province [172] 0 0
Poznan
Country [173] 0 0
Poland
State/province [173] 0 0
Szczecin
Country [174] 0 0
Portugal
State/province [174] 0 0
Coimbra
Country [175] 0 0
Portugal
State/province [175] 0 0
Lisbon
Country [176] 0 0
Portugal
State/province [176] 0 0
Porto
Country [177] 0 0
Romania
State/province [177] 0 0
Bucharest
Country [178] 0 0
Romania
State/province [178] 0 0
Cluj-Napoca
Country [179] 0 0
Romania
State/province [179] 0 0
Ovidiu
Country [180] 0 0
Slovakia
State/province [180] 0 0
Banská Bystrica
Country [181] 0 0
Slovakia
State/province [181] 0 0
Bratislava
Country [182] 0 0
Slovakia
State/province [182] 0 0
Košice
Country [183] 0 0
South Korea
State/province [183] 0 0
Bupyeong-gu
Country [184] 0 0
South Korea
State/province [184] 0 0
Busan
Country [185] 0 0
South Korea
State/province [185] 0 0
Cheongju-si
Country [186] 0 0
South Korea
State/province [186] 0 0
Daegu
Country [187] 0 0
South Korea
State/province [187] 0 0
Deagu
Country [188] 0 0
South Korea
State/province [188] 0 0
Eunpyeong-gu
Country [189] 0 0
South Korea
State/province [189] 0 0
Gangnam-gu
Country [190] 0 0
South Korea
State/province [190] 0 0
Goyang-si
Country [191] 0 0
South Korea
State/province [191] 0 0
Hwasun-gun
Country [192] 0 0
South Korea
State/province [192] 0 0
Nam-gu
Country [193] 0 0
South Korea
State/province [193] 0 0
Seongnam
Country [194] 0 0
South Korea
State/province [194] 0 0
Seoul
Country [195] 0 0
South Korea
State/province [195] 0 0
Suwon
Country [196] 0 0
South Korea
State/province [196] 0 0
Yangsan
Country [197] 0 0
Spain
State/province [197] 0 0
Badajoz
Country [198] 0 0
Spain
State/province [198] 0 0
Barcelona
Country [199] 0 0
Spain
State/province [199] 0 0
Hospitalet
Country [200] 0 0
Spain
State/province [200] 0 0
Jerez de la Frontera
Country [201] 0 0
Spain
State/province [201] 0 0
Las Palmas de Gran Canaria
Country [202] 0 0
Spain
State/province [202] 0 0
Madrid
Country [203] 0 0
Spain
State/province [203] 0 0
Málaga
Country [204] 0 0
Spain
State/province [204] 0 0
Palma
Country [205] 0 0
Spain
State/province [205] 0 0
Pamplona
Country [206] 0 0
Spain
State/province [206] 0 0
Pozuelo de Alarcón
Country [207] 0 0
Spain
State/province [207] 0 0
Santiago de Compostela
Country [208] 0 0
Spain
State/province [208] 0 0
Seville
Country [209] 0 0
Spain
State/province [209] 0 0
Valencia
Country [210] 0 0
Spain
State/province [210] 0 0
Zaragoza
Country [211] 0 0
Sweden
State/province [211] 0 0
Gothenburg
Country [212] 0 0
Switzerland
State/province [212] 0 0
Baden
Country [213] 0 0
Switzerland
State/province [213] 0 0
Fribourg
Country [214] 0 0
Switzerland
State/province [214] 0 0
Locarno
Country [215] 0 0
Taiwan
State/province [215] 0 0
Changhua County
Country [216] 0 0
Taiwan
State/province [216] 0 0
Chiayi City
Country [217] 0 0
Taiwan
State/province [217] 0 0
Douliu
Country [218] 0 0
Taiwan
State/province [218] 0 0
Hualien City
Country [219] 0 0
Taiwan
State/province [219] 0 0
Kaohsiung City
Country [220] 0 0
Taiwan
State/province [220] 0 0
Kaohsiung Niao Sung Dist
Country [221] 0 0
Taiwan
State/province [221] 0 0
New Taipei City
Country [222] 0 0
Taiwan
State/province [222] 0 0
Taichung
Country [223] 0 0
Taiwan
State/province [223] 0 0
Tainan
Country [224] 0 0
Taiwan
State/province [224] 0 0
Taipei
Country [225] 0 0
Taiwan
State/province [225] 0 0
Taoyuan
Country [226] 0 0
Turkey (Türkiye)
State/province [226] 0 0
Adana
Country [227] 0 0
Turkey (Türkiye)
State/province [227] 0 0
Adapazari
Country [228] 0 0
Turkey (Türkiye)
State/province [228] 0 0
Ankara
Country [229] 0 0
Turkey (Türkiye)
State/province [229] 0 0
Antalya
Country [230] 0 0
Turkey (Türkiye)
State/province [230] 0 0
Edirne
Country [231] 0 0
Turkey (Türkiye)
State/province [231] 0 0
Gaziantep
Country [232] 0 0
Turkey (Türkiye)
State/province [232] 0 0
Istanbul
Country [233] 0 0
Turkey (Türkiye)
State/province [233] 0 0
Izmir
Country [234] 0 0
Turkey (Türkiye)
State/province [234] 0 0
Pendik
Country [235] 0 0
Turkey (Türkiye)
State/province [235] 0 0
Samsun
Country [236] 0 0
United Kingdom
State/province [236] 0 0
Birmingham
Country [237] 0 0
United Kingdom
State/province [237] 0 0
East Sussex
Country [238] 0 0
United Kingdom
State/province [238] 0 0
Huddersfield
Country [239] 0 0
United Kingdom
State/province [239] 0 0
London
Country [240] 0 0
United Kingdom
State/province [240] 0 0
Manchester
Country [241] 0 0
United Kingdom
State/province [241] 0 0
Torquay

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eli Lilly and Company
Address
Country
Secondary sponsor
Nil
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
AstraZeneca
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Address 0 0
Country 0 0
Phone 0 0
1-317-615-4559
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
When will data be available (start and end dates)?
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Available to whom?
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://vivli.org/


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.